CA2520255A1 - Modulateurs de tie-2 et procedes d'utilisation - Google Patents

Modulateurs de tie-2 et procedes d'utilisation Download PDF

Info

Publication number
CA2520255A1
CA2520255A1 CA002520255A CA2520255A CA2520255A1 CA 2520255 A1 CA2520255 A1 CA 2520255A1 CA 002520255 A CA002520255 A CA 002520255A CA 2520255 A CA2520255 A CA 2520255A CA 2520255 A1 CA2520255 A1 CA 2520255A1
Authority
CA
Canada
Prior art keywords
ethyl
triazol
pyridin
optionally substituted
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002520255A
Other languages
English (en)
Other versions
CA2520255C (fr
Inventor
Jeff Chen
Lisa Dalrymple
Sergey Epshteyn
Timothy Forsyth
Tai Huynh
James Leahy
Grace Mann
Larry W. Mann
Brian Ridgway
Joan C. Sangalang
Craig Takeuchi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2520255A1 publication Critical patent/CA2520255A1/fr
Application granted granted Critical
Publication of CA2520255C publication Critical patent/CA2520255C/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
CA2520255A 2003-04-09 2004-04-08 Modulateurs de tie-2 et procedes d'utilisation Expired - Fee Related CA2520255C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US46147103P 2003-04-09 2003-04-09
US60/461,471 2003-04-09
PCT/US2004/010626 WO2004091480A2 (fr) 2003-04-09 2004-04-08 Modulateurs de tie-2 et procedes d'utilisation

Publications (2)

Publication Number Publication Date
CA2520255A1 true CA2520255A1 (fr) 2004-10-28
CA2520255C CA2520255C (fr) 2014-07-08

Family

ID=33299820

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2520255A Expired - Fee Related CA2520255C (fr) 2003-04-09 2004-04-08 Modulateurs de tie-2 et procedes d'utilisation

Country Status (6)

Country Link
US (1) US8178570B2 (fr)
EP (1) EP1611123B8 (fr)
JP (1) JP4881725B2 (fr)
AU (1) AU2004229392A1 (fr)
CA (1) CA2520255C (fr)
WO (1) WO2004091480A2 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533357A (en) * 2004-01-08 2005-10-16 Millennium Pharm Inc 2-(amino-substituted)-4-aryl pyrimidines and related compounds useful for treating inflammatory diseases
WO2006039356A2 (fr) * 2004-09-29 2006-04-13 Cytovia, Inc. N-aryl-9-oxo-9h-fluorene-1-carboxamides substitues et analogues utilises comme activateurs des caspases et inducteurs de l'apoptose
AR051248A1 (es) * 2004-10-20 2007-01-03 Applied Research Systems Derivados de 3-arilamino piridina
BRPI0606872A2 (pt) * 2005-01-28 2009-07-21 Novartis Ag uso de pirimidilaminobenzamidas para o tratamento de doenças que respondem à modulação de atividade de tie-2 quinase
CN103121996B (zh) * 2006-04-19 2015-10-21 默克雪兰诺有限公司 用作mek抑制剂的杂芳基取代的芳基氨基吡啶衍生物
US8263588B2 (en) 2007-04-06 2012-09-11 Neurocrine Biosciences, Inc. Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
NZ580457A (en) 2007-04-06 2012-03-30 Neurocrine Biosciences Inc Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
UA103319C2 (en) 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
JO3078B1 (ar) 2009-11-27 2017-03-15 Janssen Pharmaceutica Nv مورفولينوثيازولات بصفتها منظمات الوستيرية نوع الفا 7 موجبة
JP2013147428A (ja) * 2010-04-27 2013-08-01 Dainippon Sumitomo Pharma Co Ltd 新規２−ヘテロアリール単環ピリミジン誘導体
EP2708537A4 (fr) * 2011-05-10 2014-10-01 Taisho Pharmaceutical Co Ltd Dérivé à cycle hétéroaromatique
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
GB2516561B (en) * 2013-03-15 2016-03-09 Aerpio Therapeutics Inc Compositions, formulations and methods for treating ocular diseases
JP2015131783A (ja) * 2014-01-14 2015-07-23 株式会社日本ファインケム アリール−１，２，４−トリアゾール誘導体の製造方法
US9598381B2 (en) * 2014-07-31 2017-03-21 Abbvie Inc. SMYD2 inhibitors
EP3541431B1 (fr) * 2016-11-16 2024-04-17 The General Hospital Corporation Agents d'imagerie de myéloperoxydase
US11066404B2 (en) 2018-10-11 2021-07-20 Incyte Corporation Dihydropyrido[2,3-d]pyrimidinone compounds as CDK2 inhibitors
US11384083B2 (en) 2019-02-15 2022-07-12 Incyte Corporation Substituted spiro[cyclopropane-1,5′-pyrrolo[2,3-d]pyrimidin]-6′(7′h)-ones as CDK2 inhibitors
TW202100520A (zh) 2019-03-05 2021-01-01 美商英塞特公司 作為cdk2 抑制劑之吡唑基嘧啶基胺化合物
WO2020205560A1 (fr) 2019-03-29 2020-10-08 Incyte Corporation Composés sulfonylamides utilisés comme inhibiteurs de la cdk2
WO2020214851A1 (fr) * 2019-04-18 2020-10-22 Aerpio Pharmaceuticals, Inc. Méthode de traitement de l'hypertension avec des activateurs de tie-2
US11447494B2 (en) 2019-05-01 2022-09-20 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
US11440914B2 (en) 2019-05-01 2022-09-13 Incyte Corporation Tricyclic amine compounds as CDK2 inhibitors
CN116348458A (zh) 2019-08-14 2023-06-27 因赛特公司 作为cdk2抑制剂的咪唑基嘧啶基胺化合物
CN119930611A (zh) 2019-10-11 2025-05-06 因赛特公司 作为cdk2抑制剂的双环胺
US11981671B2 (en) 2021-06-21 2024-05-14 Incyte Corporation Bicyclic pyrazolyl amines as CDK2 inhibitors
US11976073B2 (en) 2021-12-10 2024-05-07 Incyte Corporation Bicyclic amines as CDK2 inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MC598A1 (fr) * 1966-02-16 1967-03-21 Mauvernay Roland Yves Nouveaux composés chimiques et procédé pour leur préparation
US3647809A (en) * 1968-04-26 1972-03-07 Chinoin Gyogyszer Es Vegyeszet Certain pyridyl-1 2 4-oxadiazole derivatives
US3978054A (en) * 1974-11-29 1976-08-31 Merck & Co., Inc. 1,3,5-Trisubstituted-1,2,4-triazole compounds
AR230994A1 (es) * 1981-08-31 1984-08-31 Pfizer Procedimiento para preparar compuesto de 3'-substituido-5'-(2-amino-4-piridil)-1',2',4'-triazol
GB8829296D0 (en) 1988-12-15 1989-01-25 Ici Plc Anti-tumour compounds
JPH0813446B2 (ja) * 1990-05-30 1996-02-14 株式会社日立製作所 スリツプキヤステイング法
JP3217846B2 (ja) * 1992-03-04 2001-10-15 クミアイ化学工業株式会社 トリアゾール誘導体及び殺虫剤
WO2002032896A1 (fr) 2000-10-16 2002-04-25 Novo Nordisk A/S Derives de furazanyl-triazole destines au traitement de maladies
CA2445568A1 (fr) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Derives triazole inhibiteurs des kinases et leurs utilisations
CA2449544A1 (fr) * 2001-06-08 2002-12-19 Cytovia, Inc. 3-aryl-5-aryl-[1,2,4]-oxadiazoles et leurs analogues, activateurs des caspases et inducteurs de l'apoptose, et leurs utilisations
US20050004186A1 (en) * 2002-12-20 2005-01-06 Pfizer Inc MEK inhibiting compounds
JP2007223901A (ja) * 2004-03-24 2007-09-06 Takeda Chem Ind Ltd 複素環化合物およびその用途

Also Published As

Publication number Publication date
JP4881725B2 (ja) 2012-02-22
AU2004229392A1 (en) 2004-10-28
CA2520255C (fr) 2014-07-08
US8178570B2 (en) 2012-05-15
JP2006522813A (ja) 2006-10-05
US20060293342A1 (en) 2006-12-28
EP1611123A4 (fr) 2008-07-02
EP1611123A2 (fr) 2006-01-04
EP1611123B1 (fr) 2013-10-02
WO2004091480A2 (fr) 2004-10-28
EP1611123B8 (fr) 2013-11-13
WO2004091480A3 (fr) 2005-08-11

Similar Documents

Publication Publication Date Title
EP1611123B1 (fr) Modulateurs de tie-2 et procedes d'utilisation
EP1663204B1 (fr) Modulateurs c-kit et leurs procedes d'utilisation
AU2004230928B2 (en) Tie-2 modulators and methods of use
US7846959B2 (en) Raf modulators and methods of use
JP2015531773A (ja) スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用
WO2017201069A1 (fr) Dérivés d'oxoindoline utilisés comme modulateurs de la fonction protéique
US8710038B2 (en) Pyrazole kinase modulators and methods of use
TW201505630A (zh) 用於治療癌症之苯甲酸衍生物ｍｄｍ２抑制劑
CN103193691B (zh) 磺胺类化合物、药物组合物及其制法和应用
CN106573907B (zh) 喹啉衍生物及其用于神经退化性疾病的用途
JP4960085B2 (ja) Ｔｉｅ−２モジュレータと使用方法
WO2004026226A2 (fr) Composes, compositions et procedes
JP2021523120A (ja) セルデュラチニブ（ｃｅｒｄｕｌａｔｉｎｉｂ）の固体形態
CN119546595A (zh) 萘并呋喃取代的戊二酰亚胺类化合物的晶型、制备方法及其应用
JPH04235983A (ja) 新規キノリン誘導体およびそれを有効成分として含有する制癌剤効果増強剤
TW200539884A (en) New alkyl-containing 5-acylindolinones, the preparation thereof and their use as medicaments

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160408